Introduction: In many types of itch, the interaction between immune system cells, keratinocytes, and sensory nerves involved in the transmission of itch is quite complex. Especially for patients with chronic itching, current treatments are insufficient, and their quality of life deteriorates significantly. Objective: In this study, we aimed to investigate the role of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), cannabinoid agonist WIN 55,212-2, and nitric oxide (NO) synthase inhibitor Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) in pruritus. Methods: We created a serotonin (5-HT)-induced (50 μg/μL/mouse, i.d.) acute and acetone-ether-water (AEW)-induced chronic itching models. 17-AAG (1, 3, and 5 mg/kg, intraperitoneally [i.p.]), WIN 55,212-2 (1 mg/kg, i.p.), and L-NAME (1 mg/kg, i.p.) were applied to Balb/c mice. Results: We found that 17-AAG suppressed the scratches of mice, depending on the dose. The itch behavior was reduced by WIN 55,212-2, but L-NAME showed no antipruritic effect at the administered dose. The combined application of these agents in both pruritus models showed synergism in terms of the antipruritic effect. Our results showed that NO did not play a role in the antipruritic effect of WIN 55,212-2 and 17-AAG. Increased plasma IgE levels with AEW treatment decreased with the administration of 17-AAG (5 mg/kg, i.p.) and WIN 55,212-2. Conclusion: These results demonstrate that Hsp90 may play a role in the peripheral pathway of pruritus, and cannabinoid agonists and Hsp90 inhibitors can be used together in the treatment of pruritus.

1.
Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch.
Nat Rev Neurosci
. 2006;7(7):535–47.
2.
Metz M, Grundmann S, Ständer S. Pruritus: an overview of current concepts.
Vet Dermatol
. 2011;22(2):121–31.
3.
Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function.
Eur Heart J
. 2012;33(7):829–37, 37a–37d.
4.
Ostadhadi S, Foroutan A, Momeny M, Norouzi-Javidan A, Azimi E, Kordjazy N, et al. Evidence for the involvement of nitric oxide in cholestasis-induced itch associated response in mice.
Biomed Pharmacother
. 2016;84:1367–74.
5.
Ajayi AAL. Itching, chloroquine, and malaria: a review of recent molecular and neuroscience advances and their contribution to mechanistic understanding and therapeutics of chronic non-histaminergic pruritus.
Int J Dermatol
. 2019;58(8):880–91.
6.
Ostadhadi S, Haj-Mirzaian A, Azimi E, Mansouri P, Dehpour AR. Involvement of nitric oxide in serotonin-induced scratching in mice.
Clin Exp Dermatol
. 2015;40(6):647–52.
7.
Huang W, Ye M, Zhang LR, Wu QD, Zhang M, Xu JH, et al. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Mol Cancer
. 2014;13:150.
8.
Benjamin IJ, McMillan DR. Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease.
Circ Res
. 1998;83(2):117–32.
9.
Edwards MJ, Marks R, Dykes PJ, Merrett VR, Morgan HE, O'Donovan MR. Heat shock proteins in cultured human keratinocytes and fibroblasts.
J Invest Dermatol
. 1991;96(3):392–6.
10.
Kakeda M, Arock M, Schlapbach C, Yawalkar N. Increased expression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis.
J Am Acad Dermatol
. 2014;70(4):683–90.e1.
11.
Michel T, Vanhoutte PM. Cellular signaling and NO production.
Pflugers Arch
. 2010;459(6):807–16.
12.
Prangsaengtong O, Koizumi K, Senda K, Sakurai H, Saiki I. eNOS and Hsp90 interaction directly correlates with cord formation in human lymphatic endothelial cells.
Lymphat Res Biol
. 2011;9(1):53–9.
13.
Ulugöl A. The endocannabinoid system as a potential therapeutic target for pain modulation.
Balkan Med J
. 2014;31(2):115–20.
14.
Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States.
J Neurol Sci
. 2020;411:116717.
15.
Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets.
Psychopharmacology
. 2021;238(1):9–28.
16.
Garibyan L, Rheingold CG, Lerner EA. Understanding the pathophysiology of itch.
Dermatol Ther
. 2013;26(2):84–91.
17.
Bilir KA, Anli G, Ozkan E, Gunduz O, Ulugol A. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Clin Exp Dermatol
. 2018;43(5):553–8.
18.
Haruna T, Soga M, Morioka Y, Hikita I, Imura K, Furue Y, et al. S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission.
Pharmacology
. 2015;95(1–2):95–103.
19.
Todurga ZG, Gunduz O, Karadag CH, Ulugol A. Descending serotonergic and noradrenergic systems do not regulate the antipruritic effects of cannabinoids.
Acta Neuropsychiatr
. 2016;28(6):321–6.
20.
Inagaki N, Igeta K, Kim JF, Nagao M, Shiraishi N, Nakamura N, et al. Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80.
Eur J Pharmacol
. 2002;448(2–3):175–83.
21.
Kuraishi Y. Methods for preclinical assessment of antipruritic agents and itch mechanisms independent of mast-cell histamine.
Biol Pharm Bull
. 2015;38(5):635–44.
22.
Li Y, Chen L, Du Y, Huang D, Han H, Dong Z. Fluoxetine ameliorates atopic dermatitis-like skin lesions in BALB/c mice through reducing psychological stress and inflammatory response.
Front Pharmacol
. 2016;7:318.
23.
Abul-Husn NS, Annangudi SP, Ma'ayan A, Ramos-Ortolaza DL, Stockton SD Jr, Gomes I, et al. Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis.
PLoS One
. 2011;6(10):e25535.
24.
Bucci M, Roviezzo F, Cicala C, Sessa WC, Cirino G. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo.
Br J Pharmacol
. 2000;131(1):13–6.
25.
Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Cancer Chemother Pharmacol
. 2001;47(4):291–302.
26.
Gunduz O, Topuz RD, Todurga ZG, Duvan K, Karadag CH, Ulugol A. Effect of activation of the GLT-1 transporter by a beta-lactam antibiotic on serotonin-induced scratching behavior in mice.
Neurophysiology
. 2015;47(1):36–9.
27.
Jing PB, Cao DL, Li SS, Zhu M, Bai XQ, Wu XB, et al. Chemokine receptor CXCR3 in the spinal cord contributes to chronic itch in mice.
Neurosci Bull
. 2018;34(1):54–63.
28.
Miyamoto T, Nojima H, Shinkado T, Nakahashi T, Kuraishi Y. Itch-associated response induced by experimental dry skin in mice.
Jpn J Pharmacol
. 2002;88(3):285–92.
29.
Cevikbas F, Lerner EA. Physiology and pathophysiology of itch.
Physiol Rev
. 2020;100(3):945–82.
30.
Olek-Hrab K, Hrab M, Szyfter-Harris J, Adamski Z. Pruritus in selected dermatoses.
Eur Rev Med Pharmacol Sci
. 2016;20(17):3628–41.
31.
Tukaj S, Zillikens D, Kasperkiewicz M. Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases.
Exp Dermatol
. 2015;24(8):567–71.
32.
Dickel H, Gambichler T, Kamphowe J, Altmeyer P, Skrygan M. Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-α and IL-8/CXCL8 mRNA: new insights into the involvement of “alarmins”.
Contact Dermatitis
. 2010;63(4):215–22.
33.
Xiang X, Tu C, Li Q, Wang W, Huang X, Zhao Z, et al. Oxymatrine ameliorates imiquimod-induced psoriasis pruritus and inflammation through inhibiting heat shock protein 90 and heat shock protein 60 expression in keratinocytes.
Toxicol Appl Pharmacol
. 2020;405:115209.
34.
Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study.
Acta Dermatovenerol Croat
. 2005;13(2):97–103.
35.
Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin.
Inflamm Res
. 2003;52(6):238–45.
36.
Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Mol Pharmacol
. 1995;48(3):443–50.
37.
Maghfour J, Rietcheck HR, Rundle CW, Runion TM, Jafri ZA, Dercon S, et al. An observational study of the application of a topical cannabinoid gel on sensitive dry skin.
J Drugs Dermatol
. 2020;19(12):1204–8.
38.
Schneider G, Driesch G, Heuft G, Evers S, Luger TA, Ständer S. Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch.
Clin Exp Dermatol
. 2006;31(6):762–7.
39.
Andoh T, Kuraishi Y. Nitric oxide enhances substance P-induced itch-associated responses in mice.
Br J Pharmacol
. 2003;138(1):202–8.
40.
Haddadi NS, Foroutan A, Ostadhadi S, Azimi E, Rahimi N, Nateghpour M, et al. Peripheral NMDA receptor/NO system blockage inhibits itch responses induced by chloroquine in mice.
Acta Derm Venereol
. 2017;97(5):571–7.
41.
Haddadi NS, Shakiba S, Afshari K, Haj-Mirzaian A, Vesaghati S, Gharagozlou S, et al. Possible involvement of nitric oxide in the antipruritic effect of metformin on chloroquine-induced scratching in mice.
Dermatology
. 2020;236(2):151–9.
42.
Sud N, Sharma S, Wiseman DA, Harmon C, Kumar S, Venema RC, et al. Nitric oxide and superoxide generation from endothelial NOS: modulation by HSP90.
Am J Physiol Lung Cell Mol Physiol
. 2007;293(6):L1444–53.
43.
Siragusa M, Fröhlich F, Park EJ, Schleicher M, Walther TC, Sessa WC. Stromal cell-derived factor 2 is critical for Hsp90-dependent eNOS activation.
Sci Signal
. 2015;8(390):ra81.
44.
Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids.
J Cell Biochem
. 2001;81(4):715–23.
45.
Gercek OZ, Oflaz B, Oguz N, Demirci K, Gunduz O, Ulugol A. Role of nitric oxide in the antipruritic effect of WIN 55,212-2, a cannabinoid agonist.
Basic Clin Neurosci
. 2020 Jul–Aug;11(4):473–80.
46.
Siiskonen H, Harvima I. Mast cells and sensory nerves contribute to neurogenic inflammation and pruritus in chronic skin inflammation.
Front Cell Neurosci
. 2019;13:422.
47.
Wang Z, Lu M, Ren J, Wu X, Long M, Chen L, et al. Electroacupuncture inhibits mast cell degranulation via cannabinoid CB2 receptors in a rat model of allergic contact dermatitis.
Acupunct Med
. 2019;37(6):348–55.
48.
Parlar A, Arslan SO. CB2 agonist (AM1241) improving effect on ovalbumin-induced asthma in rats.
Iran J Pharm Res
. 2020;19(1):3–17.
49.
Yang M, Wu T, Cheng L, Wang F, Wei Q, Tanguay RM. Plasma antibodies against heat shock protein 70 correlate with the incidence and severity of asthma in a Chinese population.
Respir Res
. 2005;6(1):18.
50.
Ye C, Huang C, Zou M, Hu Y, Luo L, Wei Y, et al. The role of secreted Hsp90α in HDM-induced asthmatic airway epithelial barrier dysfunction.
BMC Pulm Med
. 2019;19(1):218.
51.
Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M. Cannabinoids for the treatment of chronic pruritus: a review.
J Am Acad Dermatol
. 2020;82(5):1205–12.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.